Ophthalmic Business News

Stand-alone use of the Omni surgical system reduced IOP and the need for IOP-lowering medications at 36 months in adults with open-angle glaucoma, according to a press release from Sight Sciences.

The first commercial cases using the Ally adaptive cataract treatment system have been performed, according to a press release from Lensar.

Opthea has secured up to $170 million in dilutive financing for the phase 3 clinical trials and pre-commercialization activities for OPT-302, under investigation to treat wet age-related macular degeneration, according to a press release.

In the 10th part of a 12-part series, Peter J. Polack, MD, FACS, discusses his third website conversion tactic.

Participants with diabetic macular edema treated with a senolytic Bcl-xL inhibitor in the phase 2 BEHOLD study experienced visual acuity improvement after 18 weeks, according to a press release from Unity Biotechnology.

The first patient has been enrolled in a prospective, randomized, multicenter study of the iTrack Advance canaloplasty device, according to a press release from Nova Eye Medical.

In May 2022, after several months of volatility across all financial markets, the S&P 500 had fallen into the second bear market in 2 years.

Lions Eye Institute for Transplant and Research has entered into an agreement to acquire SightLife, according to a press release.

Positive top-line results were reported for a phase 3 clinical study investigating APP13007 to treat inflammation and pain after cataract surgery, according to a press release from Formosa Pharmaceuticals and AimMax Therapeutics.

In this episode, Ashlie Leal, director of ophthalmology at FundamentalVR, discusses their fully immersive surgical training products, how virtual reality plays a role in training surgeons and more.